目的 探討卡瑞利珠單抗聯(lián)合化療方案治療晚期胃癌的臨床療效。方法 選擇2020年1月—2021年1月重慶市開州區(qū)人民醫(yī)院收治的80例晚期胃癌患者，根據(jù)治療方法將患者分為對照組和觀察組，每組各40例。對照組第1天靜脈滴注多西他賽注射液，75 mg/m²；第2天靜脈滴注鹽酸伊立替康注射液，75 mg/m²；第3～16天分2次口服替吉奧膠囊80 mg/m²，連續(xù)誘導化療3個周期。觀察組在對照組基礎上靜脈注射注射用卡瑞利珠單抗，200 mg，21 d為1個周期，連續(xù)免疫治療3個周期。比較兩組療效及安全性，以及治療前后血清腫瘤標志物和生活質(zhì)量差異。結(jié)果 治療后，觀察組總有效率達52.50%，顯著高于對照組的30.00%（P<0.05）。兩組治療后健康狀況調(diào)查簡表（SF-36）各項評分和總分均較治療前增加（P<0.05），且觀察組治療后SF-36各項評分和總分均顯著高于對照組（P<0.05）。兩組治療后血清癌胚抗原（CEA）、糖類抗原199（CA199）水平均較治療前降低（P<0.05），且觀察組治療后血清CEA、CA199水平明顯低于對照組（P<0.05）。治療期間，觀察組Ⅲ度及以上反應性毛細血管增生癥發(fā)生率高于對照組（P<0.05）。結(jié)論 卡瑞利珠單抗聯(lián)合化療方案治療可提高晚期胃癌治療療效，不良反應較低，并能降低血清CEA、CA19-9水平，改善患者生活質(zhì)量。

Objective To investigate the clinical efficacy of carrizumab combined with chemotherapy in treatment of advanced gastric cancer. Methods A total of 80 patients with advanced gastric cancer admitted to People's Hospital of Kaizhou District from January 2020 to January 2021 were selected and divided into control group and observation group according to treatment methods, with 40 patients in each group. Patients in the control group were iv administered with Docetaxel Injection on the first day, 75 mg/m²; Irinotecan Hydrochloride Injection was intravenously injected on the second day, 75 mg/m²; From 3 to 16 days, Tegafur,Gimeracil and Oteracil Potassium Capsules 80 mg/m² was taken orally twice daily, and induction chemotherapy was conducted for 3 consecutive cycles. Patients in the observation group were iv administered with with Carrizumab for injection, 200 mg, 21 d as a cycle, and immunotherapy lasted for 3 cycles. The therapeutic effect, serum tumor markers, and quality of life before and after treatment were compared between two groups. Results After treatment, the total effective rate of the observation group was 52.50%, which was significantly higher than 30.00% of the control group (P < 0.05). After treatment, the scores and total scores of SF-36 in two groups were increased compared with before treatment (P < 0.05), and the scores and total scores of SF-36 in the observation group were significantly higher than those in the control group (P < 0.05). After treatment, serum levels of CEA and CA199 in two groups were decreased compared with before treatment (P < 0.05), and the CEA and CA199 levels in observation group were significantly lower than those in control group after treatment (P < 0.05). During the treatment, the incidence of Ⅲ degree or above reactive capillary hyperplasia in the observation group was higher than that in the control group (P < 0.05). Conclusion Carrelizumab combined with chemotherapy can improve the curative effect of advanced gastric cancer with low adverse reactions, reduce serum CEA and CA19-9 levels, and improve the quality of life of patients.